WASHINGTON TRUST Co increased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 53,064 shares of the medical research company’s stock after buying an additional 768 shares during the quarter. WASHINGTON TRUST Co’s holdings in Amgen were worth $9,228,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the stock. Jackson Grant Investment Advisers Inc. raised its stake in Amgen by 0.8% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after buying an additional 5 shares during the period. South Texas Money Management Ltd. raised its stake in Amgen by 0.7% during the 2nd quarter. South Texas Money Management Ltd. now owns 3,223 shares of the medical research company’s stock worth $555,000 after buying an additional 22 shares during the period. Glenview Trust Co raised its stake in Amgen by 0.4% during the 2nd quarter. Glenview Trust Co now owns 6,137 shares of the medical research company’s stock worth $1,057,000 after buying an additional 25 shares during the period. Roberts Glore & Co. Inc. IL raised its stake in Amgen by 0.4% during the 2nd quarter. Roberts Glore & Co. Inc. IL now owns 7,425 shares of the medical research company’s stock worth $1,279,000 after buying an additional 27 shares during the period. Finally, WMS Partners LLC raised its stake in Amgen by 0.5% during the 2nd quarter. WMS Partners LLC now owns 6,319 shares of the medical research company’s stock worth $1,088,000 after buying an additional 33 shares during the period. 79.50% of the stock is currently owned by institutional investors and hedge funds.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Friday, March 16th. The stock was sold at an average price of $189.75, for a total transaction of $289,368.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders sold 4,575 shares of company stock valued at $838,064. 0.19% of the stock is currently owned by corporate insiders.
Several brokerages have recently commented on AMGN. Cann reissued a “buy” rating and issued a $205.00 price objective on shares of Amgen in a research note on Thursday, November 30th. Oppenheimer reissued a “buy” rating and issued a $205.00 price objective on shares of Amgen in a research note on Thursday, November 30th. BidaskClub raised Amgen from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 2nd. Goldman Sachs downgraded Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Finally, Citigroup downgraded Amgen to a “neutral” rating in a research note on Monday, December 18th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $191.72.
Amgen, Inc. (NASDAQ AMGN) opened at $182.55 on Tuesday. The stock has a market capitalization of $135,638.63, a P/E ratio of 71.03, a PEG ratio of 2.31 and a beta of 1.37. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35. Amgen, Inc. has a twelve month low of $152.16 and a twelve month high of $201.23.
Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.03 by ($0.14). The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business’s revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the company earned $2.89 earnings per share. analysts anticipate that Amgen, Inc. will post 13.25 EPS for the current year.
Amgen declared that its Board of Directors has authorized a stock repurchase plan on Thursday, February 1st that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be issued a $1.32 dividend. This represents a $5.28 annualized dividend and a dividend yield of 2.89%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio is presently 205.45%.
TRADEMARK VIOLATION WARNING: This story was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://ledgergazette.com/2018/03/20/washington-trust-co-boosts-position-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.